Cel-Sci Corp. of Alexandria, Va., has signed a processdevelopment agreement with Roger Williams Medical Center inProvidence,.R.I., to improve the company's production of BC-IL,its immune-boosting product.

The company said it is among the first to develop combinationtherapy using "natural" lymphokine and cytokine mixtures forthe treatment of cancers and immunodeficiencies.

The company's board of directors also approved a stockholderrights plan designed to ensure that its stockholders receivefair and equal treatment in the event of a proposal to acquirecontrol of the company.

Maximillian de Clara, chairman of the board, said that the planwas not adopted in response to any specific takeover attemptand that he was not aware of any such attempt.

(c) 1997 American Health Consultants. All rights reserved.